Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioniche Life Sciences, Inc.
Blackmont Capital retained by Canadian biopharma firm to assist in sale of pharma business unit
November 4th, 2005
Bioniche Life Sciences, Inc., (BNC) has retained the services of Blackmont Capital, Inc., (formerly known as First Associates) to assist in the sale of its majority ownership stake (65%, fully-diluted) in Bioniche Pharma Group Limited, a business unit of the company. The company announced the decision to sell its stake in Bioniche Pharma on September 28, 2005. The pharma business unit was established by Bioniche Life Sciences in 1992 as a means of generating revenue to support the company's strategic research and development projects. At this point in its development, Bioniche Pharma requires continued investment to reach its full potential, and...
Source: Biotech Law Weekly (2005-11-04)
|
